GE LI, PHD.
Dr. Ge Li is the Founder, Chairman and Chief Executive Officer of WuXi AppTec, a leading R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries with 12,000 employees and 25 R&D sites and offices worldwide.
A pioneer in biopharma R&D service industry in China, Dr. Li founded WuXi in December 2000 with four employees, China’s first modern chemistry hood, and a single 7,000-square-foot chemistry laboratory. During the past 15 years as its Chairman and CEO, Dr. Li has led WuXi’s rapid growth into a global R&D enabling powerhouse with a pioneering open-access platform as the cornerstone. Today, WuXi’s platform is enabling thousands of biopharma and medical device R&D programs from over 2000 collaborators worldwide.
Dr. Li's visionary leadership and achievements have won him numerous prestigious awards and honors, including the “2016 CBA Brilliant Achievement Award”, “2015 SCRIP Executive of the Year Award”, “The 25 Most Influential People in Biopharma in 2015”, “Forbes 25 Notable Chinese-Americans”, “The 60 Most Influential People during 60 Years Pharmaceutical Development in China”, and “Ernst & Young Entrepreneur of the Year China Award”.
Dr. Li earned his bachelor’s degree in Chemistry from Peking University and his doctoral degree in Organic Chemistry from Columbia University. Prior to WuXi, Dr. Li was a founding scientist at Pharmacopeia Inc., a leading combinatorial chemistry platform company.
Hans E. Bishop is one of our co-founders and has served as our Chief Executive Officer and a member of our Board of Directors since September 2013. Mr. Bishop has also served as a member of the Board of Directors of Avanir Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, since May 2012. Mr. Bishop previously served as Chairman of the Board of Genesis Biopharma, Inc., a biotechnology company, from January 2012 until November 2012. From February 2012 until October 2012, Mr. Bishop was the Chief Operating Officer of PhotoThera, Inc., a late-stage medical device company owned by Warburg Pincus, and he continued working with Warburg Pincus as an Executive in Residence until October 2013. Mr. Bishop previously served as Executive Vice President and Chief Operating Officer at Dendreon Corporation, a cancer cell therapy company, from January 2010 to September 2011.
Mr. Bishop has also served as the President of the Specialty Medicine Business at Bayer Healthcare Pharmaceuticals, Inc. from December 2006 to January 2010, where he was responsible for a diverse portfolio of neurology, oncology, and hematology products. Mr. Bishop was employed by Chiron Corporation as Senior Vice President of Global Commercial Operations until its sale to Novartis Corporation. Mr. Bishop received a B.Sc. in Chemistry from Brunel University in London.
ROBERT M. HERSHBERG, M.D., PH.D.
Robert M. Hershberg, M.D., Ph.D. currently serves as Executive Vice President/ Head of Business Development and Global Alliances at Celgene Corporation, a publicly-traded biopharmaceutical company. In this capacity, Rob serves as a member of the Executive Committee and is responsible for business development in all therapeutic areas within the Celgene portfolio. Prior to his current role, Rob served as Chief Scientific Officer at Celgene. He joined Celgene in August 2014 to lead the scientific and early clinical efforts in Immuno-Oncology (I-O) and established a Therapeutic Center of Excellence for I-O in Seattle.
Prior to joining Celgene, Rob was the President and Chief Executive Officer of VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company, which he co-founded in 2006. Prior to co-founding VentiRx, Dr. Hershberg served as Senior Vice President and Chief Medical Officer at Dendreon Corporation, a biotechnology company, where he led the clinical, regulatory and biometrics groups, focusing on the development of Provenge® in metastatic prostate cancer. From 2001 to 2003, Dr. Hershberg was the Vice President of Medical Genetics at Corixa, a pharmaceutical company (acquired by GlaxoSmithKline in 2005).
Earlier in his career, Dr. Hershberg served as an Assistant Professor at Harvard Medical School and an Associate Physician at the Brigham and Women's Hospital in Boston, Massachusetts. Dr. Hershberg holds clinical and research faculty positions at the University of Washington School of Medicine and is a member of the board of directors of Adaptive Biotechnologies Corp., Nanostring Technology (NASDAQ: NSTG) and Silverback Therapeutics. He completed his undergraduate degree in molecular biology and medical degree (M.D.) at UCLA, and his Ph.D. in biology at the Salk Institute.